This project indicated that not only a vast number of novel potentially functional variants in a total of 231 pharmacogenes was identified but also demonstrated the value of whole - genome sequencing
for pharmacogenomic testing by capturing over 18,000 variants per individual in these pharmacogenes.
Not exact matches
«Precision medicine is already positively affecting providers (
for example, by reducing ED visits by 30 % through application of molecular profiling treatment strategy); payers ($ 25 billion expected annual spending on genetic
tests by 2021, and 45 % of FDA approvals were geared toward targeted therapies in 2013); and pharma (the
pharmacogenomics market is expected to be $ 7.5 billion by 2017).»
Although
pharmacogenomics has great potential
for clinical utility when used accordingly, many third party payers, including Medicare, may only cover
testing for certain disease diagnoses and usually after therapy failure.
deCODE plans to use its
pharmacogenomic work to develop and market a
test that can be used to target the prescription of glucocorticoids to those patients
for whom these compounds provide the most effective relief with the least possible side - effects.
Proponents of personalized medicine were thankful
for several developments that show this trend is picking up speed: CVS followed Medco's example in expanding
pharmacogenomic testing, while biotech and pharma companies, as well as the National Cancer Institute, stepped up their investment in the field.